论文部分内容阅读
本文报告46例不能手术切除的原发性中晚期肝癌患者经肝动脉灌注免疫及化疗加栓塞后,35例(76%)临床症状改善,23例(50%)AFP值明显降低或降至正常.12例(26%)肿瘤体积缩小>50%,3例获得二期手术切除.作者认为:对于中晚期肝癌患者应采取不放弃治疗的观点,肝动脉灌注免疫和化疗及栓塞仍可使大多数病人临床症状改善,生存期延长,少数病人还可获得二期手术;并对肝动脉化疗栓塞治疗后二期手术的时间提出了商榷.
In this report, 46 patients with unresectable primary middle-advanced liver cancer were treated with hepatic artery perfusion and chemotherapy plus embolization. Clinical symptoms were improved in 35 patients (76%), and AFP values were significantly reduced or decreased to normal in 23 patients (50%). In 12 cases (26%), the tumor volume was reduced by >50%, and 3 cases received secondary surgical resection. The authors believe that for patients with advanced liver cancer who should not give up treatment, hepatic artery perfusion and chemotherapy and embolization can still make large Most of the patients had improved clinical symptoms and prolonged survival. A small number of patients could also obtain secondary surgery; and the time for second-stage surgery after hepatic arterial chemoembolization was presented.